BEGIN:VCALENDAR VERSION:2.0 PRODID:-//ChamberMaster//Event Calendar 2.0//EN METHOD:PUBLISH X-PUBLISHED-TTL:P1H REFRESH-INTERVAL:P1H CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:America/Chicago BEGIN:DAYLIGHT RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU DTSTART:20070101T000000 TZOFFSETFROM:-0600 TZOFFSETTO:-0500 TZNAME:Central Daylight Time END:DAYLIGHT BEGIN:STANDARD RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU DTSTART:20070101T000000 TZOFFSETFROM:-0500 TZOFFSETTO:-0600 TZNAME:Central Standard Time END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Chicago:20230414T200000 DTEND;TZID=America/Chicago:20230414T210000 X-MICROSOFT-CDO-ALLDAYEVENT:FALSE SUMMARY:VIRTUAL: MAO April 14\, 2023 Meeting featuring Tony Realini\, MD DESCRIPTION:SLT Today and TomorrowTony Realini\, MD\, MPH\nProfessor of Ophthalmology\nWest Virginia UniversityEducational Objectives:Following this presentation\, the participants will be better able to:\n1. incorporate primary and adjunctive SLT into clinical practice.\n2. prepare for a new glaucoma treatment paradigm driven by SLT 2.0.Tony Realini\, MD\, MPH attended the University of North Carolina at Chapel Hill for his undergraduate education\, medical school\, internship and residency\, followed by a one-year fellowship in glaucoma at the University of Louisville\, studying under glaucoma specialists Thom Zimmerman\, MD\, PhD and Robert Fechtner\, MD. He also received an MPH degree from the University of Pittsburgh's Graduate School of Public Health in 2010. He is now a tenured Professor of Ophthalmology at West Virginia University\, where he serves as the vice chair for clinical research\, glaucoma fellowship director\, and glaucoma service director. He is active in eye research\, has received numerous research grants (including four from the National Eye Institute)\, and has published widely in ophthalmic medical journals. He currently serves as the study chair for the multicenter randomized COAST trial (Clarifying the Optimal Application of SLT Therapy)\, which seeks to establish the optimal energy and repeat interval for primary selective laser trabeculoplasty in newly-diagnosed and treatment-na ve patients with mild-moderate primary open-angle glaucoma or high risk ocular hypertension.\nACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Minnesota Medical Association and University of Minnesota\, Department of Ophthalmology. The Minnesota Medical Association (MMA) is accredited by the ACCME to provide continuing medical education for physicians. CME STATEMENT The Minnesota Medical Association designates this Regularly Scheduled Series for a maximum of 1.0 AMA PRA Category 1 Credit(s) . Physicians should claim only the credit commensurate with the extent of their participation in the activity. This meeting is being co-sponsored by the University of Minnesota.Thank you to our Exhibitor:Genentech X-ALT-DESC;FMTTYPE=text/html:
SLT Today and Tomorrow
Tony Realini\, MD\, MPH
Professor of Ophthalmology
West Virginia University
Educational Objectives:
Following this presentation\, the participants will be better able to:
1. incorporate primary and adjunctive SLT into clinical practice.
2. prepare for a new glaucoma treatment paradigm driven by SLT 2.0.
Tony Realini\, MD\, MPH attended the University of North Carolina at Chapel Hill for his undergraduate education\, medical school\, internship and residency\, followed by a one-year fellowship in glaucoma at the University of Louisville\, studying under glaucoma specialists Thom Zimmerman\, MD\, PhD and Robert Fechtner\, MD. He also received an MPH degree from the University of Pittsburgh&rsquo\;s Graduate School of Public Health in 2010. He is now a tenured Professor of Ophthalmology at West Virginia University\, where he serves as the vice chair for clinical research\, glaucoma fellowship director\, and glaucoma service director. He is active in eye research\, has received numerous research grants (including four from the National Eye Institute)\, and has published widely in ophthalmic medical journals. He currently serves as the study chair for the multicenter randomized COAST trial (Clarifying the Optimal Application of SLT Therapy)\, which seeks to establish the optimal energy and repeat interval for primary selective laser trabeculoplasty in newly-diagnosed and treatment-naï\;ve patients with mild-moderate primary open-angle glaucoma or high risk ocular hypertension.
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Minnesota Medical Association and University of Minnesota\, Department of Ophthalmology. The Minnesota Medical Association (MMA) is accredited by the ACCME to provide continuing medical education for physicians.  \;  \; \;
CME STATEMENT The Minnesota Medical Association designates this Regularly Scheduled Series for a maximum of 1.0 AMA PRA Category 1 Credit(s)&trade\; . Physicians should claim only the credit commensurate with the extent of their participation in the activity. This meeting is being co-sponsored by the University of Minnesota.
Thank you to our Exhibitor: